0TDD Stock Price and Chart — LSE:0TDD

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

Key facts today

Novo Nordisk is now the largest European company by market cap at $365.8 billion, following a 2.5% rise in shares due to its obesity drug amycretin entering late-stage development.

Novo Nordisk signed an $812 million licensing deal with U.S. biotech Deep Apple for a weight-loss drug and announced a partnership with Septerna to develop oral small-molecule weight-loss drugs.

Novo Nordisk will skip early development and start late-stage trials for its obesity drug, amycretin, in early 2026. Analysts note a potential 22% weight loss, aiming for market entry by 2028.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.